Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia

  • Thoas Fioretos
  • Per-Gunnar Nilsson
  • P Åman
  • Sverre Heim
  • Ulf Kristoffersson
  • C Malm
  • B Simonsson
  • Ingemar Turesson
  • Felix Mitelman
Publishing year: 1993
Language: English
Pages: 1225-1231
Publication/Series: Leukemia
Volume: 7
Issue: 8
Document type: Journal article
Publisher: Nature Publishing Group

Abstract english

We have analyzed the M-bcr breakpoint position in 133 Philadelphia-positive chronic myeloid leukemia patients and correlated the findings with clinical, hematologic, and cytogenetic data. We also investigated the splicing pattern of the BCR-ABL mRNA in 30 patients, using reverse transcriptase PCR. No statistically significant differences were found between breakpoint position within M-bcr and clinical parameters at diagnosis, the karyotypic evolution pattern, or the leukemic phenotype during blast crisis. Furthermore, the breakpoint position within M-bcr did not correlate with the duration of chronic phase or survival time. When the splicing pattern of the BCR-ABL mRNA was compared with the results of the genomic breakpoint mapping, it was found that approximately 60% (8/14) of the patients with a 5' break expressed b2a2 fusion mRNA, whereas all patients (10/10) with a 3' break expressed b3a2 BCR-ABL mRNA.


  • Cancer and Oncology


  • ISSN: 1476-5551
Thoas Fioretos
E-mail: thoas.fioretos [at]

Principal investigator

Division of Clinical Genetics

+46 46 222 45 95

+46 70 334 33 67